India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically. This move comes after supply chain was disrupted due to the coronavirus pandemic exposed the country’s dependence on China and raised the threat of drug shortages.
The program consists of spending on infrastructure for drug manufacturing centers and financial incentives of up to 20 per cent of incremental sales value over the next eight years, according to a government statement.
Currently, India imports almost 70 per cent of its active pharmaceutical ingredients, the chemicals that make a finished drug work, from China. Hubei province, the epicenter of the coronavirus outbreak has been major source of these ingredients. As the world’s single largest exporter of generic drugs, India is responsible for about 20 per cent of the world’s supply.
Source: IBEF
Image Courtesy: Pharmaceutical Technology
You may also like
-
India’s Steel Engine Defies Global Slowdown as Output Surges in FY26
-
India Launches IP Catalyst Platform to Turn Patents into Market-Ready Electronics and IT Products
-
Made-in-India EQ70 Pipes Signal Big Shift from Imported Offshore Steel to Domestic Manufacturing
-
AI-Powered Financial Inclusion: India’s Digital Banking Revolution Enters Its Next Phase
-
LANXESS-HPCL Partnership to Strengthen Aviation and Industrial Lubricants Market in India and SAARC Region